For the year ending 2025-12-31, GYRE made $116,588K in revenue. $5,027K in net income. Net profit margin of 4.31%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenues | 116,588 | |||
| Cost of revenues | 5,416 | |||
| Selling and marketing | 65,179 | |||
| Research and development | 13,698 | |||
| General and administrative | 20,804 | |||
| Loss on disposal of assets, net | -4 | |||
| Total operating expenses | 105,101 | |||
| Income from operations | 11,487 | |||
| Interest income, net | 1,747 | |||
| Other expense, net | -1,505 | |||
| Change in fair value of warrant liability | -2,707 | |||
| Total income before income taxes | 14,436 | |||
| Provision for income taxes | 4,556 | |||
| Net income | 9,880 | |||
| Net income attributable to noncontrolling interest | 4,853 | |||
| Net income attributable to common stockholders | 5,027 | |||
| Basic EPS | 0.06 | |||
| Diluted EPS | 0.02 | |||
| Basic Average Shares | 89,344,622 | |||
| Diluted Average Shares | 103,180,037 | |||
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)